|
| VIEW POINT |
|
| Year : 2010 | Volume
: 56
| Issue : 4 | Page : 328-331 |
Selective estrogen receptor modulators promising for cardiac syndrome X
YX Chen, NS Luo, YQ Lin, WL Yuan, SL Xie, RQ Nie, JF Wang
Department of Cardiology, The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, Guangdong, China
Correspondence Address:
J F Wang
Department of Cardiology, The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, Guangdong
China
 Source of Support: Partly supported by National Natural Science Foundation of China to JingFeng Wang (No.30971262), Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.70936
Cardiac syndrome X (CSX) is defined as a typical anginal-like chest pain with a transient ischemic electrocardiogram, but without abnormal coronary angiography. It is usually accepted that endothelial dysfunction, inflammation, oxidative stress and estrogen deficiency are the main reasons of CSX. There are some methods to treat CSX including statins, b blocker, angiotensin converting enzyme inhibitors, nitrates, estrogen, and so on. The estrogen replacement therapy (ERT), in particular, has been reported by many researchers to significantly reduce the frequency of chest pain after administration of estrogen, which has been explained as estrogen acting on its receptor to improve the endothelial function. However, it has been suggested that ERT must not be used for coronary heart disease due to its adverse effects. However, some selective estrogen receptor modulators (SERMs) can inhibit inflammatory response as well as oxidative stress, and improve the endothelial function, to reduce the occurrence of chest pain. Here, we hypothesize that SERMs may be the beneficial selection for patients with CSX.
[FULL TEXT] [PDF]*
|
